The challenges of measuring socioeconomic inequality in pharmacoepidemiology studies

Social conditions like socioeconomic status (SES) are critical sources of health disparities. In pharmacoepidemiology research, our ability to measure SES in retrospective, real-world clinical data remain challenged by a lack of patient-reported data. Some broadly accepted concepts can be measured at the individual level, such as income, poverty, and education. Community-level measures such as the Centers for Disease Control and Prevention's Social Vulnerability Index also exist. After reflecting on these existing measures and discussing the challenges for leveraging them with real-world data, we offer three recommendations that we believe could improve the ability of pharmacoepidemiologists to better measure and interrogate the effect of SES in their own research. These recommendations include a greater collection of patient-reported metrics, reduced reliance on ZIP Codes and ZIP Code Tabulation Areas for creating community-level measures of deprivation, and the inclusion of GIS and demography specialists within pharmacoepidemiology teams. This article is part of a Special Collection on Pharmacoepidemiology.

Authors

Institutions

Publication Details

Journal
American Journal of Epidemiology
Published
2024-09-17
DOI
https://doi.org/10.1093/aje/kwae360
Citations
2
Primary Topic
Primary Care and Health Outcomes
Type
article
Field-Weighted Citation Impact
1.70
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The challenges of measuring socioeconomic inequality in pharmacoepidemiology studies

Christopher Prener, Sarah J. Willis, Katharina Schley, Amanda Miles
2 citations
American Journal of Epidemiology
Primary Care and Health Outcomes
1.70
article

The challenges of measuring socioeconomic inequality in pharmacoepidemiology studies

Christopher Prener, Sarah J. Willis, Katharina Schley, Amanda Miles
article en
2 citations

Abstract

Social conditions like socioeconomic status (SES) are critical sources of health disparities. In pharmacoepidemiology research, our ability to measure SES in retrospective, real-world clinical data remain challenged by a lack of patient-reported data. Some broadly accepted concepts can be measured at the individual level, such as income, poverty, and education. Community-level measures such as the Centers for Disease Control and Prevention's Social Vulnerability Index also exist. After reflecting on these existing measures and discussing the challenges for leveraging them with real-world data, we offer three recommendations that we believe could improve the ability of pharmacoepidemiologists to better measure and interrogate the effect of SES in their own research. These recommendations include a greater collection of patient-reported metrics, reduced reliance on ZIP Codes and ZIP Code Tabulation Areas for creating community-level measures of deprivation, and the inclusion of GIS and demography specialists within pharmacoepidemiology teams. This article is part of a Special Collection on Pharmacoepidemiology.

American Journal of EpidemiologyVol. 194(5)
Pfizer (United States) (US), Pfizer (Germany) (DE)
Reduced inequalities
Openalex Percentile: Top 14%
Primary Care and Health Outcomes
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The challenges of measuring socioeconomic inequality in pharmacoepidemiology studies — Christopher Prener, Sarah J. Willis, et al. · American Journal of Epidemiology (2024) | TGRS Research Map | TGRS